Virobay Appoints Thomas J. Dietz, Ph.D. To The Virobay Board Of Directors
MENLO PARK, Calif., Feb. 25, 2014
MENLO PARK, Calif., Feb. 25, 2014 /PRNewswire/ --Virobay, Inc., a privately
held biotechnology firm with a broad portfolio of cathepsin protease
inhibitors for the treatment of neuropathic pain, autoimmune diseases, liver
diseases and dermatological diseases, today announced that Thomas J. Dietz,
Ph.D., has joined the board of Virobay as an independent director effective
February 13, 2014.
Dr. Dietz has more than 20 years of successful life-sciences industry
experience. Prior to his current role as Chairman and CEO of Waypoint
Holdings, a financial holdings and services company, Dr. Dietz was co-CEO and
then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based
investment bank and institutional brokerage firm from 2004 to 2009, when the
firm was acquired by Wedbush Securities. Dr. Dietz served as head of the
investment banking division at Wedbush until November 2010. Prior to becoming
CEO at Pacific Growth, Dr. Dietz served as the firm's Director of Equities
Research and was an award-winning biotechnology and biopharmaceutical
analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, he was a
member of the research faculty in the Department of Medicine, University of
California, San Francisco and the VA Medical Center. Dr. Dietz currently
serves as Chairman of Galleon Pharmaceuticals, Inc. and Director of Glialogix
and Transcept Pharmaceuticals, Inc. as well as on the board of trustees of the
West Bay Region of the Sutter Health system that includes California Pacific
Medical Center, San Francisco. Dr. Dietz holds a Ph.D. in molecular biology
and biochemistry from Washington University, St. Louis, and was a National
Science Foundation Post-Doctoral Fellow.
"The addition of Tom Dietz further enhances the Board's pharmaceutical
industry expertise," stated Robert Booth, President and Chief Executive
Officer. "Tom's extensive experience and knowledge will enable him to provide
important advice as Virobay moves through the next stage of its corporate
"Virobay has a novel drug discovery and development platform based on
cathepsin inhibitors. This is coupled with an experienced management team and
a promising pipeline of molecules in clinical development," stated Dr. Dietz.
"I look forward to working with the Virobay board and team to capitalize upon
these assets and to create shareholder value."
Virobay is a leader in the design, synthesis and development of small molecule
inhibitors of cysteine proteases, a diverse class of enzyme proteases that are
key mediators in a variety of diseases, including neuropathic pain,
autoimmunity, liver diseases, and dermatological diseases. Virobay was
founded upon a rich industry legacy of intensive research and development
focused on the cathepsin family of cysteine proteases. Today, Virobay
possesses a trove of maturing assets, including an advancing clinical pipeline
and well-characterized libraries of highly potent and selective inhibitors
with drug-like pharmacokinetics consistent with the potential for oral
once-daily dosing in humans.
Virobay's unique expertise in the structure-based design of this class of
inhibitors includes extensive understanding of the properties of the cysteine
protease active site, detailed knowledge of the cell biology of this enzyme
family and a collection of pharmacodynamic biomarkers, as well as a deep
understanding of the medicinal chemistry required to achieve superior levels
of potency, pharmacokinetics, safety and specificity. Virobay's clinical
pipeline currently includes product candidates in neuropathic pain,
dermatology, autoimmune disease, and liver fibrosis. For more information
please visit our website: www.virobayinc.com.
Robert Booth, PhD
President and Chief Executive Officer
SOURCE Virobay, Inc.
Press spacebar to pause and continue. Press esc to stop.